The Safety and Efficacy of Mesenchymal Stem Cells in the Treatment of Type 2 Diabetes- A Literature Review.
diabetes
mesenchymal stem cells
regenerative medicine
stem cell
Journal
Diabetes, metabolic syndrome and obesity : targets and therapy
ISSN: 1178-7007
Titre abrégé: Diabetes Metab Syndr Obes
Pays: New Zealand
ID NLM: 101515585
Informations de publication
Date de publication:
2023
2023
Historique:
received:
04
10
2022
accepted:
24
01
2023
entrez:
21
3
2023
pubmed:
22
3
2023
medline:
22
3
2023
Statut:
epublish
Résumé
Type 2 diabetes (T2D) is the most common type of diabetes, affecting 6.28% of the population worldwide. Over the decades, multiple therapies and drugs have been developed to control T2D, but they are far from a long-term solution. Stem cells are promising as novel regenerative treatments, especially mesenchymal stem cells (MSCs), which are highly versatile in their regenerative and paracrine capabilities and characteristics. This makes them the most commonly used adult stem cells and ideal candidates to treat diabetes. To assess the safety and efficacy of mesenchymal stem cells (MSCs) in treating Type 2 diabetes (T2D) in humans. Mesenchymal stem cell-based treatments were studied in 262 patients. A total of 6 out of 58 trials fit our inclusion criteria in the last five years. The treatment of patients with MSCs reduced the dosage of anti-diabetic drugs analyzed over a follow-up period of 12 months. The effective therapy dosage ranged from 1×10 This analysis concludes that MSC treatment of type 2 diabetes is safe and effective. A larger sample size is required, and the trials should also study the effect of differentiated MSCs as insulin-producing cells.
Identifiants
pubmed: 36941907
doi: 10.2147/DMSO.S392161
pii: 392161
pmc: PMC10024492
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
769-777Informations de copyright
© 2023 Mathur et al.
Déclaration de conflit d'intérêts
The authors report no conflicts of interest in this work.
Références
Front Med. 2011 Mar;5(1):94-100
pubmed: 21681681
Stem Cells Dev. 2017 Apr 1;26(7):471-481
pubmed: 28006991
Curr Neuropharmacol. 2022 Mar 27;:
pubmed: 35339180
Chem Rev. 2015 Jun 10;115(11):4719-43
pubmed: 25918949
Chin Med J (Engl). 2011 Nov;124(22):3622-8
pubmed: 22340214
J Cell Mol Med. 2012 Sep;16(9):2094-103
pubmed: 22151542
Cureus. 2021 Feb 26;13(2):e13563
pubmed: 33815977
Exp Ther Med. 2016 Sep;12(3):1857-1866
pubmed: 27588104
Ann Clin Transl Neurol. 2022 Feb;9(2):206-220
pubmed: 35106961
Int J Mol Sci. 2018 Dec 18;19(12):
pubmed: 30567403
Stem Cell Res Ther. 2017 Dec 22;8(1):288
pubmed: 29273086
Curr Diab Rep. 2014 Aug;14(8):508
pubmed: 24919749
J Mol Endocrinol. 2017 Oct;59(3):R109-R120
pubmed: 28739632
Cardiovasc Diabetol. 2018 Jun 8;17(1):83
pubmed: 29884191
Diabetes Ther. 2017 Jun;8(3):475-487
pubmed: 28484968
Stem Cells Transl Med. 2021 Sep;10(9):1266-1278
pubmed: 34080789
Biomark Insights. 2016 Jul 03;11:95-104
pubmed: 27398023
Lancet Oncol. 2021 Oct;22(10):1378-1390
pubmed: 34529931
J Med Econ. 2015 Jan;18(1):45-55
pubmed: 25266815
Diabetes Care. 2020 Jan;43(Suppl 1):S4-S6
pubmed: 31862743
Int J Mol Sci. 2020 Aug 30;21(17):
pubmed: 32872570
Diabetol Metab Syndr. 2019 Feb 18;11:20
pubmed: 30820250
Zhonghua Nei Ke Za Zhi. 2016 May 1;55(5):349-54
pubmed: 27143183
Transpl Int. 2016 Jun;29(6):727-39
pubmed: 27062063
Am J Transplant. 2016 Feb;16(2):518-26
pubmed: 26595767